atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
November 08 2021 - 8:30AM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that it plans to host a
conference call on Monday, November 15, 2021 at 8:30 a.m. ET to
discuss its financial results for the quarter ended September 30,
2021 and provide a business update.
To access the live conference call, please dial 877-407-3982
from the United States, or +1 (201) 493-6780 internationally, using
the conference ID: 13724750. The live and archived webcast of this
call will be available in the “Events” section of the atai Life
Sciences website at ir.atai.life.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's mission is to bridge the gap between what the mental
healthcare system currently provides and what patients need. atai
has offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including without limitation
statements regarding atai’s participation in upcoming conferences
and presentations and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors discussed under the caption “Risk Factors” in atai's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities
and Exchange Commission (“SEC”) on June 21, 2021, as such factors
may be updated from time to time in atai's other filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. atai disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, whether as a result of
new information, future events or otherwise, other than to the
extent required by applicable law.
Contact Information
Investor Contact:Chad MesserVP, Investor Relations, atai Life
SciencesEmail: chad@atai.life
Media Contact:Camilla DormerVP, Communications, atai Life
SciencesEmail: camilla@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024